even a germ gets smarter at some point....The FDA was just buying time to understand ,i think now they may have made it at lest 5 steps under us here.
don't you think with the clear evidence of Sarepta's dmd drug along side a great safety profile that common sense with avail here and get this drug to the market as quick as possible.A drug such as this with a certain exact gene to the exon treatment would get through someones head that it will work '' it should do the same on one ''as the same as many,it is no way around this type of drug.
Chimerix climbs after FDA agrees to allow pilot trial of brincidofovir
Shares of pharmaceutical company Chimerix (CMRX) are rising after the company announced last night that it had reached a deal with the FDA to initiate a pilot trial of its brincidofovir drug for the treatment of adenovirus infections. Reports from CNN and other media outlets earlier this week indicated that Chimerix has been under increasing pressure to help a dying 7-year-old boy from Virginia with the experimental drug. WHAT'S NEW: The FDA agreed to allow Chimerix to immediately launch the study and also committed to working "expeditiously" with Chimerix to design a Phase 3 study of the drug, the company announced. Brincidofovir could be the first broad-spectrum antiviral for the prevention and treatment of clinically significant infections and diseases caused by DNA viruses, the company said. ANALYST REACTION: In a note to investors earlier today, Canaccord Genuity analyst Ritu Baral wrote that the new pilot trial underscores the potential of brincidofovir, and the unmet need for a treatment for adenovirus infections. The drug could greatly improve post-treatment care for patients at risk of contracting a number of double-stranded DNA viral infections, according to the analyst, who kept a $34 price target and Buy rating on the stock. WHAT'S NOTABLE: Shares of Sarepta Therapeutics (SRPT) are also rising significantly today. Sarepta is working with the FDA on the design of a Phase III trial of eteplirsen, its drug for the treatment of Duchenne muscular dystrophy. PRICE ACTION: In mid-afternoon trading, Chimerix surged $3.10, or 14.9%, to $23.90. Sarepta shares are up $1.55, or 5.79%, to $28.34.
Some of the smartest people out there are right here on this board,the long term people here do understand quite a bit about this science and other forms of science.If a long term person here has stayed here for this long what would you think about them?
lawsuit is nothing more than a worthless piece of paper and time...they are trying to get something other than monies here
worst case.....part of the profits..wow...
From what i have researched ,i do not see a problem
they claim they have a patent on anything greater than 30mg ....what a joke
Newfields family fights for DMD treatment for 11-year-old son
By CORINNE HOLROYD
March 11, 2014 - 2:00 AM
NEWFIELDS— Lucas Currier, 11, climbed into a chair lift to get up the stairs in his family's Newfields home last week as his mother, Linda Currier, watched it ascend. He then showed off his sports-themed room and talked about his favorite baseball team, the Red Sox, and his new favorite player on the team, Dustin Pedroia, as he rested on his bed.
Lucas had to use the chair lift and rest on his bed because his muscles have been slowly degenerating due to a disorder called Duchenne muscular dystrophy (DMD).
According to Race to Yes, a campaign run by parental advocates who are pushing for DMD treatment, one in 3,500 boys are born with DMD. It is also the "number one genetic killer of children" and there is currently no approved treatment.
Linda, however, is one of thousands of people petitioning for the Food and Drug Administration to put the drug eteplirsen back on the accelerate program after it was taken off in November.
"There's that drug, it's in its phase two clinical trial (and) the results are just incredible," she said.
Eteplirsen, developed by Sarepta Therapeutics, is designed to skip the part of the patient's gene which prevents dystrophin, a protein in the body, from playing its part in muscle repair.
this week...............very good chance